Pacira Pharmaceuticals (PCRX) stock fell over 5% on Friday, February 28th, following the release of the company's Q4 2024 earnings report and full-year 2025 financial guidance. The plummet occurred despite a continuation of strong revenue growth for the company's flagship products EXPAREL and ZILRETTA in Q4.
The decline appears to be driven by near-term concerns around increasing investments across R&D and commercial operations pressuring profitability in 2025. Specifically, Pacira raised R&D expense guidance by 11% versus Q4 2024 run rate to fund key pipeline programs like the Phase 2 study for osteoarthritis drug candidate PCRX-201, as well as regulatory efforts for ZILRETTA and iovera line extensions. SG&A expense guidance was also increased 8% to support new marketing initiatives including planned direct-to-consumer pilot programs for EXPAREL.
Additionally, while the new NOPAIN Act coverage and EXPAREL J-code are expected to drive sales growth beginning in the second half of 2025, management cautioned that customer integration could take time, creating potential volatility in near-term performance. There are also lingering uncertainties around the commercial potential of Pacira's newly acquired pipeline assets from the GQ Bio acquisition, as those programs are still in the early preclinical stages.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。